Anticonvulsants in bipolar disorders: Current research and practice and future directions

Bipolar Disorders

Volumn 11, Issue SUPPL. 2, 2009, Pages 20-33

  Bowden, Charles L ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Anticonvulsants; Bipolar disorder; Carbamazepine; Depression; Lamotrigine; Mania; Treatment; Valproate

Indexed keywords

ANTICONVULSIVE AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CARBAMAZEPINE; ETIRACETAM; FLUOXETINE PLUS OLANZAPINE; GABAPENTIN; HALOPERIDOL; IMIPRAMINE; LAMOTRIGINE; LITHIUM; NEUROLEPTIC AGENT; OLANZAPINE; OXCARBAZEPINE; PHENYTOIN; PLACEBO; RETIGABINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; TIAGABINE; TOPIRAMATE; VALPROATE SEMISODIUM; VALPROIC ACID; ZONISAMIDE;

ACCIDENTAL INJURY; ADD ON THERAPY; ADJUVANT THERAPY; AGRANULOCYTOSIS; ALOPECIA; ANOREXIA; ANTICONVULSANT ACTIVITY; ANXIETY DISORDER; APLASTIC ANEMIA; BIPOLAR DEPRESSION; BIPOLAR DISORDER; CALCIUM SIGNALING; CEREBELLUM ATROPHY; CLINICAL TRIAL; COGNITIVE DEFECT; COORDINATION DISORDER; DEPRESSION; DIPLOPIA; DIZZINESS; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ERUPTION; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENZYME INHIBITION; FATIGUE; FETUS DISEASE; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HUMAN; HYPOMANIA; HYPONATREMIA; LEUKOCYTE COUNT; LEUKOPENIA; LIVER DYSFUNCTION; LIVER TOXICITY; LOW DRUG DOSE; MANIA; NAUSEA; NEURAL TUBE DEFECT; NONHUMAN; PANCREATITIS; PHARYNGITIS; PRIORITY JOURNAL; RECURRENT DISEASE; RELAPSE; REMISSION; REVIEW; SEIZURE; SIDE EFFECT; SOMNOLENCE; SUICIDAL BEHAVIOR; THROMBOCYTE; THROMBOCYTOPENIA; TREMOR; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT CHANGE; WEIGHT GAIN; WEIGHT REDUCTION; XEROSTOMIA;

ANIMALS; ANTICONVULSANTS; BIOMEDICAL RESEARCH; BIPOLAR DISORDER; CLINICAL TRIALS AS TOPIC; HUMANS;

EID: 66649127822     PISSN: 13985647     EISSN: 13995618     Source Type: Journal    
DOI: 10.1111/j.1399-5618.2009.00708.x     Document Type: Review

References (89)

1. Lambert PA, Carraz G, Borselli S, Carbel S. Action neuropsychotrope d'un nouvel anti-epileptique: Le depamide. Ann Med Psychol 1966; 1: 707-710.
2. Takezaki H, Hanaoka M. The use of carbamazepine (Tegretol) in the control of manic depressive psychosis and other manic, depressive states. Seishin Shinkeigaku Zasshi (Psychiatria et Neurologia Japonica) 1971; 13: 173-183.
3. Heres S, Davis J, Maino K, Ketzinger E, Kissling W, Leucht S. Why olanzapine beats risperidone, risperidone beat quetiapine, and quetiapine beats olanzapine: An exploratory analysis of head-to-head comparison studies of second-generation antipsychotics. Am J Psychiatry 2006; 163: 185-194.
4. Bowden CL, McElroy SL. History of the development of valproate for treatment of bipolar disorder. J Clin Psychiatry 1995; 56: 3-5.
5. Weisler RH, Calabrese JR, Bowden CL, Ascher JA, DeVeaugh-Geiss J, Evoniuk G. Discovery and development of lamotrigine for bipolar disorder: A story of serendipity, clinical observations, risk taking, and persistence. J Affect Disord 2008; 108: 1-9.
6. Schou M, Juel-Nielsen N, Stromgren E, Voldby H. The treatment of manic psychoses by the administration of lithium salts. J Neurol Neurosurg Psychiatry 1954; 17: 250-260.
7. Pope HG Jr, McElroy SL, Keck PE Jr, Hudson JI. Valproate in the treatment of acute mania: A placebo-controlled study. Arch Gen Psychiatry 1991; 48: 62-68.
8. Bowden CL, Brugger AM, Swann AC et al. Efficacy of divalproex vs lithium and placebo in the treatment of mania. JAMA 1994; 271: 918-924.
9. Weisler RH, Keck PE Jr, Swann AC et al. Extended-release carbamazepine capsules as monotherapy for acute mania in bipolar disorder: A multicenter, randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2005; 66: 323-330.
10. Weisler RH, Kalali AH, Ketter TA, SPD417 Study Group. A multicenter, randomized, double-blind, placebo-controlled trial of extended-release carbamazepine capsules as monotherapy for bipolar disorder patients with manic or mixed episodes. J Clin Psychiatry 2004; 65: 478-484.
11. Smith LA, Cornelius V, Warnock A, Bell A, Young AH. Effectiveness of mood stabilizers and antipsychotics in the maintenance phase of bipolar disorder: A systematic review of randomized controlled trials. Bipolar Disord 2007; 9: 394-412.
12. Smith LA, Cornelius V, Warnock A, Tacchi MJ, Taylor D. Pharmacological interventions for acute bipolar mania: A systematic review of randomized placebo-controlled trials. Bipolar Disord 2007; 9: 551-560.
13. Cohen J. Statistical Power Analysis for the Behavioral Sciences, 2nd edn. Hillsdale, NJ: Lawrence Erlbaum Associates Publishers, 1988.
14. Bowden CL, Swann AC, Calabrese JR et al. A randomized, placebo-controlled, multicenter study of divalproex sodium extended release in the treatment of acute mania. J Clin Psychiatry 2006; 67: 1501-1510.
15. Swann AC, Bowden CL, Calabrese JR, Dilsaver SC, Morris DD. Pattern of response to divalproex, lithium, or placebo in four naturalistic subtypes of mania. Neuropsychopharmacol 2002; 26: 530-536.
16. Bowden CL. Acute and maintenance treatment with mood stabilizers. Int J Neuropsychopharmacol 2003; 6: 269-275.
17. Uhlenhuth EH, Matuzas W, Warner TD, Thompson PM. Growing placebo response rate: The problem in recent therapeutic trials? Psychopharmacol Bull 1997; 33: 31-39.
18. Tohen M, Ketter TA, Zarate CA. Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: A 47-week study. Am J Psychiatry 2003; 160: 1263-1271.
19. Zajecka J, Weisler R, Sachs G, Swann AC, Wozniak P, Sommerville KW. A comparison of the efficacy, safety and tolerability of divalproex sodium and olanzapine in the treatment of bipolar disorder. J Clin Psychiatry 2002; 63: 1148-1155.
20. Tohen M, Vieta E, Goodwin G et al. Olanzapine versus Divalproex versus placebo in the treatment of mild to moderate mania: A randomized, 12-week, Double-Blind Study. J Clin Psychiatry 2008; 69: 1776-1789.
21. Bowden CL, Gogus A, Grunze H, Haggstrom L, Rybakowski J, Vieta E. A 12-week, open, randomized trial comparing sodium valproate to lithium in patients with bipolar I disorder suffering from a manic episode. Int Clin Psychopharmacol 2008; 23: 254-262.
22. Vasudev K, Goswami U, Kohli K. Carbamazepine and valproate monotherapy: feasibility, relative safety and efficacy, and therapeutic drug monitoring in manic disorder. Psychopharmacology 2000; 150: 15-23.
23. Müller-Oerlinghausen B, Retzow A, Henn FA, Giedke H, Walden J. Valproate as an adjunct to neuroleptic medication for the treatment of acute episodes of mania: A prospective, randomized, double-blind, placebo-controlled, multicenter study. J Clin Psychopharmacol 2000; 20: 195-203.
24. McElroy SL, Keck PE Jr, Stanton SP, Tugrul KC, Bennett JA, Strakowski SM. A randomized comparison of divalproex oral loading versus haloperidol in the initial treatment of acute psychotic mania. J Clin Psychiatry 1998; 59: 142-146.
25. Kowatch RA, Suppes T, Carmody TJ et al. Effect size of lithium, divalproex sodium, and carbamazepine in children and adolescents with bipolar disorder. J Am Acad Child Adolesc Psychiatry 2000; 39: 713-720.
26. Yatham LN, Grossman F, Augustyns I, Vieta E, Ravindran A. Mood stabilisers plus risperidone or placebo in the treatment of acute mania. International, double-blind, randomised controlled trial. Br J Psychiatry 2003; 182: 141-147.
27. Tohen M, Bowden CL, Smulevich AB et al. Olanzapine plus carbamazepine v. carbamazepine alone in treating manic episodes. Br J Psychiatry 2008; 192: 135-143.
28. Wagner KD, Kowatch RA, Emslie GJ et al. A double-blind, randomized, placebo-controlled trial of oxcarbazepine in the treatment of bipolar disorder in children and adolescents. Am J Psychiatry 2008; 163: 1179-1186.
29. Kushner SF, Khan A, Lane R, Olson WH. Topiramate monotherapy in the management of acute mania: Results of four double-blind placebo-controlled trials. Bipolar Disord 2006; 8: 15-27.
30. Frye MA, Ketter TA, Kimbrell TA et al. A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. J Clin Psychopharmacol 2000; 20: 607-614.
31. Pande AC, Crockatt JG, Janney CA, Werth JL, Tsaroucha G. Gabapentin in bipolar disorder: A placebo-controlled trial of adjunctive therapy. Gabapentin Bipolar Disorder Study Group. Bipolar Disord 2000; 2: 249-255.
32. Pande AC, Davidson JR, Jefferson JW et al. Treatment of social phobia with gabapentin: A placebo-controlled study. J Clin Pharmacol 2004; 24: 141-149.
33. Otto MW, Simon NM, Frank E et al. Prospective 12-month course of bipolar disorder in out-patients with and without comorbid anxiety disorders. Br J Psychiatry 2006; 189: 20-29.
34. Helbich F, Tran Van Minh A, Hendrich J, Watschinger K, Dolphin AC. Time course and specificity of the pharmacological disruption of the trafficking of voltage-gated calcium channels by gabapentin. Channels 2008; 2: 4-9.
35. Goldsmith DR, Wagstaff AJ, Ibbotson T, Perry C. Lamotrigine: A review of its use in bipolar disorder. Drugs 2003; 63: 2029-2050.
36. Mishory A, Yaroslavsky Y, Bersudsky Y, Belmaker RH. Phenytoin as an antimanic anticonvulsant: A controlled study. Am J Psychiatry 2000; 157: 463-465.
37. De Marcos FA, Ghizoni E, Kobayashi E, Li LM, Centers for Disease Control and Prevention (CDC). Cerebellar volume and long-term use of phenytoin. Seizure 2003; 12: 312-315.
38. Bowden CL, Calabrese JR, McElroy SL et al. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Arch Gen Psychiatry 2000; 57: 481-489.
39. Soares-Weiser K, Bravo VY, Beynon S et al. A systematic review and economic model of the clinical effectiveness and cost-effectiveness of interventions for preventing relapse in people with bipolar disorder. Health Technol Assess 2007; 11: Iii-iv, ix-206.
40. McElroy SL, Bowden CL, Collins MA, Wozniak PJ, Keck PE, Calabrese JR. Relationship of open acute mania treatment to blinded maintenance outcome in bipolar I disorder. J Affect Disord 2008; 107: 127-133.
41. Lambert PA, Venaud G. Comparative study of valpromide versus lithium as prophylactic treatment in affective disorders. Nervure 1992; 5: 57-65.
42. Bowden CL, Swann AC, Calabrese JR et al. Maintenance clinical trials in bipolar disorder: Design implications of the divalproex-lithium-placebo study. Psychopharmacol Bull 1997; 33: 693-699.
43. Tohen M, Chengappa KN, Suppes T et al. Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser vs mood stabiliser alone. Br J Psychiatry 2004; 184: 337-345.
44. Keck PE Jr, Bowden CL, Meinhold JM, Prihoda TJ, Baker JD, Wozniak PJ. Relationship between serum valproate and lithium levels and efficacy and tolerability in bipolar maintenance therapy. Int J Psychiatry Clin Pract 2005; 9: 271-277.
45. Calabrese JR, Shelton MD, Rapport DJ et al. A 20-month, double-blind, maintenance trial of lithium versus divalproex in rapid-cycling bipolar disorder. Am J Psychiatry 2005; 162: 2152-2161.
46. Bowden CL, Calabrese JR, Sachs G, Swann A, Akthar S, DeVeaugh-Geiss J. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry 2003; 60: 392-400.
47. Calabrese JR, Bowden CL, Sachs GS, Ascher JA, Monaghan E, Rudd DG. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. J Clin Psychiatry 1999; 60: 79-88.
48. Goodwin GM, Bowden CL, Calabrese JR et al. A pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder. J Clin Psychiatry 2004; 65: 432-441.
49. Calabrese JR, Suppes T, Bowden CL et al. A double-blind placebo-controlled prophylaxis study of lamotrigine in rapid cycling bipolar disorder. J Clin Psychiatry 2000; 61: 841-850.
50. Bowden CL, Calabrese JR, McElroy SL et al. The efficacy of lamotrigine in rapid cycling and non-rapid cycling patients with bipolar disorder. Biol Psychiatry 1999; 45: 953-958.
51. Calabrese JR, Vieta E, Shelton MD. Latest maintenance data on lamotrigine in bipolar disorder. Eur Neuropsychopharmacol 2003; 13: S57-S66.
52. Bowden CL, Asnis GM, Ginsberg LD, Behtley B, Leadbetter R, White R. Safety and tolerability of lamotrigine for bipolar disorder. Drug Saf 2004; 3: 173-184.
53. Bowden CL, Calabrese JR, Ketter TA, Sachs GS, White RL, Thompson TR. Impact of lamotrigine and lithium on weight in obese and nonobese patients with bipolar I disorder. Am J Psychiatry 2006; 163: 1199-1201.
54. Bowden CL, Edwards S, Evoniuk G. Open-labeled, concomitant use of lamotrigine and other medications for bipolar disorder. CNS Spectr 2008; 13: 79-83.
55. Bowden CL. Lamotrigine in the treatment of bipolar disorder. Expert Opin Pharmacother 2002; 10: 1513-1519.
56. Greil W, Kleindienst N. The comparative prophylactic efficacy of lithium and carbamazepine in patients with bipolar I disorder. Int Clin Psychopharmacol 1999; 14: 277-281.
57. Hartong EG, Moleman P, Hoogduin CA, Broekman TG, Nolen WA, Litcar Group. Prophylactic efficacy of lithium versus carbamazepine in treatment-naive bipolar patients. J Clin Psychiatry 2003; 64: 144-151.
58. Calabrese JR, Huffman RF, White RL et al. Lamotrigine in the acute treatment of bipolar depression: Results of five double-blind, placebo-controlled clinical trials. Bipolar Disord 2008; 10: 323-333.
59. Bowden CL, Mitchell P, Suppes T. Lamotrigine in the treatment of bipolar depression. Eur Neuropsychopharmacol 1999; 9: S113-S117.
60. van der Loos ML, Mulder PG, Hartong EG et al. Efficacy and safety of lamotrigine as add-on treatment to lithium in bipolar depression: A multicenter, double-blind, placebo-controlled trial. J Clin Psychiatry 2008; 70: 223-231.
61. Brown EB, McElroy S, Keck PE et al. A 7-week, randomized, double-blind trial of olanzapine/fluoxetine combination versus lamotrigine in the treatment of bipolar I depression. J Clin Psychiatry 2006; 67: 1025-1033.
62. Davis LL, Bartolucci A, Petty F. Divalproex in the treatment of bipolar depression: A placebo-controlled study. J Affect Disord 2005; 85: 259-266.
63. Ghaemi NS, Gilmer WS, Goldberg JF et al. Divalproex in the treatment of acute bipolar depression: A preliminary double-blind, randomized, placebo-controlled pilot study. J Clin Psychiatry 2007; 68: 1839-1840.
64. Gyulai L, Bowden CL, McElroy SL et al. Maintenance efficacy of divalproex in the prevention of bipolar depression. Neuropsychopharmacology 2003; 28: 1374-1382.
65. Kemp DE, Keming G, Calabrese JR. Antiepileptic drugs in the treatment of rapid-cycling bipolar disorder and bipolar depression. In: McElroy S, Keck PE Jr, Post RM eds. Antiepileptic Drugs to Treat Psychiatric Disorders. London: Informa Healthcare, 2008: 155-176.
66. Anand A, Bukhari L, Jennings SA et al. A preliminary open-label study of zonisamide treatment for bipolar depression in 10 patients. J Clin Psychiatry 2005; 66: 195-198.
67. McElroy S, Suppes P, Keck PE Jr et al. Open-label adjunctive zonisamide in the treatment of bipolar disorders: A prospective trial. J Clin Psychiatry 2005; 66: 617-624.
68. Pande AC, Pollack MH, Crockatt J et al. Placebo-controlled study of gabapentin treatment of panic disorder. J Clin Psychopharmacol 2000; 20: 467-471.
69. Pande AC, Davidson JR, Jefferson JW et al. Treatment of social phobia with gabapentin: A placebo-controlled study. J Clin Psychopharmacol 1999; 19: 341-348.
70. Desarkar P, Das B, Sinha VK. Adjuvant levetiracetam in adolescent mania. J Clin Psychopharm 2007; 27: 215-216.
71. Grunze H, Langosch J, Born C, Schaub G, Walden J. Levetiracetam in the treament of acute mania: An open add-on study with an on-off-on design. J Clin Psychiatry 2003; 64: 781-784.
72. Kyomen HH. The use of levetiracetam to decrease mania in elderly bipolar patients. Am J Geriatr Psychiatry 2006; 14: 985.
73. Grunze H, Erfurth A, Marcuse A, Amann B, Normann C, Walden J. Tiagabine appears not to be efficacious in acute mania. J Clin Psychiatry 1999; 60: 759-762.
74. Suppes T, Chisholm KA, Dhavale D et al. Tiagabine in treatment refractory bipolar disorder: A clinical case series. Bipolar Disord 2002; 4: 283-289.
75. Amann B, Sterr A, Vieta E, Stampfer R, Walden J, Grunze H. An exploratory open trial on safety and efficacy of the anticonvulsant retigabine in acute manic patients. J Clin Pharmacol 2006; 26: 534-536.
76. Jeavons PM, Clark JE, Harding GF. Valproate and curly hair. Lancet 1977; 1: 359.
77. Bowden CL. Valproate. Bipolar Disord 2003; 5: 189-202.
78. Bowden CL, Janicak PG, Orsulak P et al. Relation of serum valproate concentration to response in mania. Am J Psychiatry 1996; 153: 765-770.
79. Redmond JR, Jamison K, Bowden CL. Lamotrigine combined with divalproex or lithium for bipolar disorder: A case series. CNS Spectr 2006; 11: 915-918.
80. Johannessen SI, Battino D, Berry DJ et al. Therapeutic drug monitoring of the newer antiepileptic drugs. Ther Drug Monit 2003; 25: 347-363.
81. Wang PW, Ketter TA, Becker OV, Nowakowska C. New anticonvulsant medication uses in bipolar disorder. CNS Spectr 2003; 8: 930-932 941-947.
82. Post RM. Psychotrophic mechanisms of action of antiepileptic drugs in mood disorder. In: McElroy S, Keck PE Jr, Post RM eds. Antiepileptic Drugs to Treat Psychiatric Disorders. London: Informa Healthcare, 2008: 379-399.
83. Einat H, Yuan P, Gould TD et al. The role of the extracellular signal-regulated kinase signaling pathway in mood modulation. J Neurosci 2003; 23: 7311-7316.
84. Rao JS, Bazinet RP, Rapoport SI, Lee H-J. Chronic treatment of rats with sodium valproate downregulates frontal cortex NF-kB DNA binding activity and COX-2 mRNA. Bipolar Disord 2007; 9: 513-520.
85. Shaltiel G, Shamir A, Shapior J et al. Valproate decreases inositol biosynthesis. Biol Psychiatry 2004; 56: 868-874.
86. Quiroz JA, Gray NA, Kato T, Manji HK. Mitchondrially mediated plasticity in the pathophysiology and treatment of bipolar disorder. Neuropsychopharmacology 2008; 33: 2551-2565.
87. Dokucu ME, Yu L, Taghert PH. Lithium- and valproate-induced alterations in circadian locomotor behavior in Drosophila. Neuropsychopharmacology 2005; 30: 2216-2224.
88. Schroeder FA, Lin CL, Crucio WE, Akbarian S. Antidepressant-like effects of the histone deacetylase inhibitor, sodium butyrate, in the mouse. Biol Psychiatry 2007; 62: 55-64.
89. Bowden CL. Bipolar pathophysiology and development of improved treatments: Review and recommendations for innovative studies. Brain Res 2008; 1235: 92-97.